PERSEIDA was an observational, prospective study assessing cfDNA RAS, BRAF and EGFR mutations (using IdyllaTM) in first-line mCRC, RAS wild-type (baseline tumor-tissue biopsy) patients (cohort 2). This evidence concerns the gene BRAF and neoplasm.